HRP20140993T1 - Otkrivanje i lijeäśenje shizofrenije - Google Patents

Otkrivanje i lijeäśenje shizofrenije Download PDF

Info

Publication number
HRP20140993T1
HRP20140993T1 HRP20140993AT HRP20140993T HRP20140993T1 HR P20140993 T1 HRP20140993 T1 HR P20140993T1 HR P20140993A T HRP20140993A T HR P20140993AT HR P20140993 T HRP20140993 T HR P20140993T HR P20140993 T1 HRP20140993 T1 HR P20140993T1
Authority
HR
Croatia
Prior art keywords
schizophrenia
pyridoxamine
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Application number
HRP20140993AT
Other languages
English (en)
Croatian (hr)
Inventor
Masanari Itokawa
Toshio Miyata
Makoto Arai
Original Assignee
Renascience Co., Ltd.
Tokyo Metropolitan Institute Of Medical Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renascience Co., Ltd., Tokyo Metropolitan Institute Of Medical Science filed Critical Renascience Co., Ltd.
Publication of HRP20140993T1 publication Critical patent/HRP20140993T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20140993AT 2007-08-20 2008-07-31 Otkrivanje i lijeäśenje shizofrenije HRP20140993T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007214047A JP5288365B2 (ja) 2007-07-17 2007-08-20 統合失調症の検査および治療
PCT/JP2008/063803 WO2009025159A1 (ja) 2007-08-20 2008-07-31 統合失調症の検査および治療

Publications (1)

Publication Number Publication Date
HRP20140993T1 true HRP20140993T1 (hr) 2014-12-19

Family

ID=40378067

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140993AT HRP20140993T1 (hr) 2007-08-20 2008-07-31 Otkrivanje i lijeäśenje shizofrenije

Country Status (11)

Country Link
US (2) US8809329B2 (enExample)
EP (2) EP2662453A3 (enExample)
JP (1) JP5288365B2 (enExample)
CY (1) CY1115640T1 (enExample)
DK (1) DK2189537T3 (enExample)
ES (1) ES2515168T3 (enExample)
HR (1) HRP20140993T1 (enExample)
PL (1) PL2189537T3 (enExample)
PT (1) PT2189537E (enExample)
SI (1) SI2189537T1 (enExample)
WO (1) WO2009025159A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143762A1 (ko) * 2009-06-12 2010-12-16 (주)바이오니아 리보핵산 분해효소 활성억제용 화합물 및 이를 포함하는 핵산 보관용 용기
JP5840124B2 (ja) * 2010-05-14 2016-01-06 公益財団法人東京都医学総合研究所 統合失調症の検出方法
CN102993191B (zh) * 2012-12-18 2015-05-27 苏州大学 一种含有吖内酯与吡唑啉酮的杂环手性化合物及其衍生物、合成方法及用途
JP6585060B2 (ja) 2014-08-29 2019-10-02 株式会社レナサイエンス ピリドキサミン化合物及びチアミン化合物を組み合わせてなる医薬組成物
KR101796390B1 (ko) * 2015-07-24 2017-11-09 동국대학교 산학협력단 Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물
JP6105111B1 (ja) 2016-03-02 2017-03-29 国立大学法人東北大学 自閉スペクトラム症改善用組成物
CN110022769B (zh) * 2017-07-07 2022-09-27 松下知识产权经营株式会社 信息提供方法、信息处理系统、信息终端及信息处理方法
JP6924964B2 (ja) * 2017-07-07 2021-08-25 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
CN109982639A (zh) * 2017-07-07 2019-07-05 松下知识产权经营株式会社 信息提供方法、信息处理系统、信息终端及信息处理方法
JP7270600B2 (ja) 2018-02-27 2023-05-10 キッコーマン株式会社 新規酵素及びそれを用いたペントシジンの測定方法
JP7680957B2 (ja) * 2019-08-27 2025-05-21 キッコーマン株式会社 ペントシジンの測定方法及び測定用キット

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52102431A (en) 1976-02-25 1977-08-27 Kyowa Hakko Kogyo Co Ltd Remedies for mental disorder
JP3507884B2 (ja) * 2000-03-07 2004-03-15 新潟大学長 遺伝子発現を指標とする統合失調症の客観的診断法
ATE389014T1 (de) 2001-01-31 2008-03-15 Vlaams Interuniv Inst Biotech Phosphorylierte glyoxalase i und deren verwendung
JP2003038198A (ja) 2001-07-27 2003-02-12 Univ Niigata 精神分裂病により発現量が変化する遺伝子を規定する核酸を解析する方法
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
JP2003212795A (ja) 2002-01-15 2003-07-30 Japan Science & Technology Corp 精神分裂病の診断薬
AU2003244205A1 (en) 2002-07-04 2004-01-23 Mitsubishi Pharma Corporation Method of examining and diagnosing integration dysfunction syndrome
JP2004251865A (ja) 2003-02-19 2004-09-09 Takashi Muramatsu 統合失調症およびアルツハイマー病の検査薬
JP4143498B2 (ja) 2003-07-31 2008-09-03 独立行政法人科学技術振興機構 統合失調症の判定方法
JPWO2005030737A1 (ja) 2003-09-30 2006-12-07 三共株式会社 テトラゾール環又はチアゾリジンジオン環を有するフェニレン誘導体
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
KR101205748B1 (ko) 2003-12-05 2012-11-28 토카이 유니버시티 에듀케이셔널시스템 단백질 개질물 형성 저해제
JP2005278490A (ja) 2004-03-29 2005-10-13 Japan Science & Technology Agency 統合失調症に関与する生物学的マーカーの判定方法およびその利用
JP5079503B2 (ja) * 2005-06-07 2012-11-21 株式会社インバイオテックス ラジカルスカベンジャー及び活性酸素消去剤
TW200720261A (en) 2005-08-31 2007-06-01 Sankyo Co Phenylene derivatives

Also Published As

Publication number Publication date
JP2009039088A (ja) 2009-02-26
US20140335517A1 (en) 2014-11-13
EP2189537A1 (en) 2010-05-26
JP5288365B2 (ja) 2013-09-11
EP2189537B1 (en) 2014-10-08
EP2662453A2 (en) 2013-11-13
US20120065198A2 (en) 2012-03-15
US8809329B2 (en) 2014-08-19
US20110028470A1 (en) 2011-02-03
CY1115640T1 (el) 2017-01-04
DK2189537T3 (da) 2014-10-27
EP2662453A3 (en) 2014-02-26
SI2189537T1 (sl) 2014-11-28
PL2189537T3 (pl) 2015-01-30
WO2009025159A1 (ja) 2009-02-26
PT2189537E (pt) 2014-10-30
EP2189537A4 (en) 2010-08-11
ES2515168T3 (es) 2014-10-29

Similar Documents

Publication Publication Date Title
HRP20140993T1 (hr) Otkrivanje i lijeäśenje shizofrenije
NL300871I2 (nl) ixazomib en farmaceutisch aanvaardbare zouten en esters daarvan, zoals ixazomibcitraat
HRP20241239T1 (hr) Novi heterociklički derivati korisni kao shp2 inhibitori
NO2020035I1 (no) cefiderokol, eventuelt på formen av et farmasøytisk akseptabelt salt eller solvat
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
ME03016B (me) Derivat piridina
MX2010005824A (es) Derivados de aminotiazol.
NO20081830L (no) Farmasøytisk middel for beskyttelse av motorisk nerve i en pasient med amyotrofisk lateralsklerose
SI2720698T1 (sl) Metoda dajanja 4-((1R,3S)-6-kloro-3-fenil-indan-1-IL)-1,2,2-trimetil-piperazina in njegovih soli pri zdravljenju shizofrenije
NO20092104L (no) Nye 1,2-dihydroquinolinderivater, farmasøytisk sammensetning inneholdende slike, samt anvendelse derav
LT2996473T (lt) Kompozicijos ir būdai, skirti aktyvuoti nuo "interferono geno stimuliatoriaus" priklausomą signalinį kelią
JP2012092123A5 (enExample)
PH12015500209A1 (en) Partially saturated nitrogen-containing heterocyclic compound
JP2019516735A5 (enExample)
SI2470518T1 (sl) Derivati 2,5-furan dikarboksilata in njihova uporaba kot plastifikatorji
MX2014002833A (es) Derivados fungicidas de 3-fenil[(heterociclilmetoxi)imino]metil}-1 ,2,4-oxadiazol-5(4h)-ona sustituidos en 4.
EA201300990A1 (ru) Парентеральное введение тапентадола
JP2015533163A5 (enExample)
HRP20151091T1 (hr) UPORABA 24-norUDCA
CL2014002048A1 (es) Compuestos derivados de 4-(benzoimidazol-2-il)-tiazol y derivados aza relacionados; composicion farmaceutica; y uso en la prevencion y el tratamiento de trastornos autoinmunes, inflamatorios, enfermedades infecciosas, entre otras.
WO2009068468A3 (en) Pyridine compounds
IL237636B (en) 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-(as8)-6-oxo-hexahydro-pyrrolo[1,2-a]pyrazin-2-yl)-piperidine -1- carboxylic acid [1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or a pharmaceutical acceptable salt thereof for use in the treatment of chronic itching
EP2950822A4 (en) PHARMACEUTICAL PREPARATION FOR THE PROTECTION OF WOUNDS BY HEMOSTASIS OR TO PREVENT ADHESION IN THE STOMACH DARM TRACT
HRP20171742T1 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
PH12015500012A1 (en) Benzodioxole derivative and preparation method and use thereof